Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 390 participants.
Also called NCT05934526
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 390 participants
- Sponsor
- GB002, Inc.
- Registry
-
NCT05934526
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Poland, Portugal, Romania, Saudi Arabia, Serbia, Singapore, South Korea, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05934526. Randomized; double masking; primary purpose treatment. Start 2023-12-28 (actual); primary completion 2025-11-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Seralutinib
- Intervention (Device)
- Generic Dry Powder Inhaler
- Lead sponsor
- GB002, Inc.
Record details
- Record id
cardio:ct-nct05934526- Content hash
64c323eccb784e530cd0c8aa09336f28ae18284e865494226726c68eefcbfb08